To the Editor: Despite safety recommendations, the increased availability of personal protective equipment, and the implementation of improved disposal systems, high-risk needlestick injuries continue to occur in unacceptably high numbers in healthcare settings.1 Design features of needle devices are relevant to their high injury risk. For example, butterflytype devices with needle-shielding features to protect against needlestick injuries showed a 25% reduction in needlesticks in a clinical trial.2 Any other risk-reducing design enhancements that can be incorporated into butterfly-type devices should be promoted and evaluated, particularly those intended for blood drawing, because of their disproportionate involvement in the transmission of bloodborne pathogens. In a recent study on devicespecific sharps injuries among healthcare workers, of all hollow-bore needles, conventional butterfly needles were associated with the highest injury rate per 100,000 devices used.3 This finding is consistent with the high rate of injury from butterfly-type needles documented in the Italian study on occupational risk of human immunodeficiency virus (HIV) that we reported previously.4 Since 1994, our data collection has been expanded to include all occupational exposures, regardless of source patient status, using the Exposure Prevention Information Network surveillance system.5 Of a total of 7,240 percutaneous injuries reported through December 31, 1996, 2,079 (29%) injuries were caused by butterfly-type needles. Our data show that more high-risk injuries (those involving blood-filled hollow-bore needles) are caused by butterfly-type needles than by any other device.1,4 Butterfly-type needles are notorious for producing the “cobra effect” against users when the spiral tubing recoils during disassembly and disposal. This is due to the length of the tubing and the fact that it is wound in a tight coil in its package. Although butterfly-type needles were designed primarily for intravenous therapy, they are used primarily for blood drawing. In the above-mentioned study, the highest use of butterfly-type needles was among laboratory phlebotomists. Similarly, in 569 (27%) butterfly-related needlesticks reported in the Italian Study on Occupational Risk of HIV— Exposure Prevention Information Network study, the device was used to draw blood, and 176 (31%) of these incidents occurred while putting the butterfly into a disposal container. These data demonstrate that, in relation to current practice, butterflytype devices frequently are used for blood drawing, a different procedure than that for which they were designed. We suggest that butterflytype devices intended for blood drawing should have only a short length of tubing and that the tubing should not be packaged in coils. The effectiveness of these kinds of devices should be evaluated.
[1]
C. L. Barnes,et al.
Vancomycin-resistance enterococcus
,
2000
.
[2]
R. L. Sinkowitz,et al.
Epidemiology of vancomycin usage at a children's hospital, 1993 through 1995.
,
1997,
The Pediatric infectious disease journal.
[3]
G. H. Tignor,et al.
Device-specific sharps injury and usage rates: an analysis by hospital department.
,
1997,
American journal of infection control.
[4]
J. Gerberding,et al.
Evaluation of safety devices for preventing percutaneous injuries among health-care workers during phlebotomy procedures--Minneapolis-St. Paul, New York City, and San Francisco, 1993-1995.
,
1997,
MMWR. Morbidity and mortality weekly report.
[5]
L. Rice,et al.
Vancomycin resistance in the enterococcus. Relevance in pediatrics.
,
1995,
Pediatric clinics of North America.
[6]
Elaine Larson,et al.
Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).
,
1995,
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[7]
G. Ippolito,et al.
Device-specific risk of needlestick injury in Italian health care workers.
,
1994,
JAMA.
[8]
P. Lietman,et al.
Serum vancomycin concentrations: reappraisal of their clinical value.
,
1994,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9]
D. Longo,et al.
A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.
,
1986,
The New England journal of medicine.